【聚焦】复星医药猛攻240亿市场，新品欲抢国内首仿

米内网08-13

精彩内容8月13日，复星医药（徐州）提交了瑞维那新吸入溶液4类仿制上市申请获得CDE承办。该产品是一款呼吸系统吸入剂，迈兰的原研产品于今年6月获批进口。目前复星医药报产在审的呼吸系统用药中有6款为吸入剂，集团正全力抢攻这个240亿热销市场。图1：复星医药（徐州）最新申报的产品来源：CDE官网图2：迈兰的瑞维那新吸入溶液项目情况来源：米内网项目进度数据库瑞维那新吸入溶液是迈兰开发的一款长效毒蕈碱...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2559434985?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-13 16:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2559434985","market":"us","top_or_hot":-1,"title":"【聚焦】复星医药猛攻240亿市场，新品欲抢国内首仿","media":"米内网","content":"<div>\n<p>精彩内容8月13日，复星医药（徐州）提交了瑞维那新吸入溶液4类仿制上市申请获得CDE承办。该产品是一款呼吸系统吸入剂，迈兰的原研产品于今年6月获批进口。目前复星医药报产在审的呼吸系统用药中有6款为吸入剂，集团正全力抢攻这个240亿热销市场。图1：复星医药（徐州）最新申报的产品来源：CDE官网图2：迈兰的瑞维那新吸入溶液项目情况来源：米内网项目进度数据库瑞维那新吸入溶液是迈兰开发的一款长效毒蕈碱...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813161533a485e660&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【聚焦】复星医药猛攻240亿市场，新品欲抢国内首仿</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【聚焦】复星医药猛攻240亿市场，新品欲抢国内首仿\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-13 16:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813161533a485e660&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容8月13日，复星医药（徐州）提交了瑞维那新吸入溶液4类仿制上市申请获得CDE承办。该产品是一款呼吸系统吸入剂，迈兰的原研产品于今年6月获批进口。目前复星医药报产在审的呼吸系统用药中有6款为吸入剂，集团正全力抢攻这个240亿热销市场。图1：复星医药（徐州）最新申报的产品来源：CDE官网图2：迈兰的瑞维那新吸入溶液项目情况来源：米内网项目进度数据库瑞维那新吸入溶液是迈兰开发的一款长效毒蕈碱...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813161533a485e660&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MED","symbol_name":"快验保","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813161533a485e660&s=b","article_id":"2559434985","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813161533a485e660&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2559434985","pubTimestamp":1755072390,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"目前复星医药报产在审的呼吸系统用药中有6款为吸入剂，集团正全力抢攻这个240亿热销市场。原研产品2020年在国内申报临床，随后在2024年申报进口上市，并在2025年6月获批进入中国市场。米内网数据显示，倍特药业在2025年6月19日首家提交了瑞维那新吸入溶液的4类仿制上市申请，随后齐鲁制药、科伦药业、复星医药等国内明星药企纷纷加入首仿争夺战，截至目前抢仿企业已超过10家，竞争异常激烈。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MED":"快验保","BK4532":"文艺复兴科技持仓","BK4183":"个人用品"},"translate_title":"[Focus] Fosun Pharma storms the 24 billion market, and new products want to grab the first domestic imitation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MED":1},"content_text":"精彩内容8月13日，复星医药（徐州）提交了瑞维那新吸入溶液4类仿制上市申请获得CDE承办。该产品是一款呼吸系统吸入剂，迈兰的原研产品于今年6月获批进口。目前复星医药报产在审的呼吸系统用药中有6款为吸入剂，集团正全力抢攻这个240亿热销市场。图1：复星医药（徐州）最新申报的产品来源：CDE官网图2：迈兰的瑞维那新吸入溶液项目情况来源：米内网项目进度数据库瑞维那新吸入溶液是迈兰开发的一款长效毒蕈碱拮抗剂，为FDA批准的首款每日仅需使用一次的长效雾化支气管扩张剂，适用于慢性阻塞性肺病（COPD）患者的维持治疗。原研产品2020年在国内申报临床，随后在2024年申报进口上市，并在2025年6月获批进入中国市场。米内网数据显示，倍特药业在2025年6月19日首家提交了瑞维那新吸入溶液的4类仿制上市申请，随后齐鲁制药、科伦药业、复星医药等国内明星药企纷纷加入首仿争夺战，截至目前抢仿企业已超过10家，竞争异常激烈。从用药途径来看，复星医药（含子公司）早前在呼吸系统用药市场获批了20多款产品，涉及口服药和注射剂，暂无吸入剂获批。图3：呼吸系统用药（化+生）吸入剂的销售情况来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），呼吸系统用药（化+生）吸入剂的销售规模在2021年、2023-2024年均保持在240亿元以上。表1：复星医药报产在审的呼吸系统用药情况来源：米内网中国申报进度（MED）数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2559434985","isCrawlerRequest":true}